Quoin Pharmaceuticals gets FDA Fast Track for QRX003 peeling skin syndrome

Quoin Pharmaceuticals said QRX003 has received Fast Track designation from the FDA for peeling skin syndrome. The company said this is the first-ever Fast Track designation granted for a therapy targeting peeling skin syndrome and the second Fast Track designation for QRX003, alongside Netherton syndrome. Quoin said the designation is intended to facilitate development and speed regulatory review for therapies addressing serious conditions with significant unmet medical need.